Compare ADMA Biologics Inc (ADMA) vs Vanguard S&P 500 Growth Index Fund ETF (VOOG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Vanguard S&P 500 Growth Index Fund ETF — how do they compare? ADMA Biologics Inc trades at $9.18 (market cap $2.13B), while Vanguard S&P 500 Growth Index Fund ETF trades at $81.8. The key difference: Vanguard S&P 500 Growth Index Fund ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | VOOG | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $20.38 | $85.11 |
52-Week Low | $7.60 | $65.32 |
Enterprise Value | $2.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
VOOG trades at $82.41, up 1.22% today, with a bullish technical outlook from moving averages but neutral oscillators. The ETF completed a 1:6 stock split in April 2026 to enhance accessibility. Recent news highlights its low 0.07% expense ratio and strong long-term growth focus on S&P 500 constituents, though short interest rose significantly in March 2026.
Outlook remains positive due to cost efficiency and growth stock exposure, but risks include tech sector volatility and high valuations. Investors benefit from diversification but should monitor market sentiment shifts amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Vanguard S&P 500 Growth Index Fund ETF
VOOG is an index-based ETF that tracks the S&P 500 Growth Index, composed of the growth-oriented companies within the S&P 500. It selects constituents based on three key metrics—sales growth, the ratio of earnings change to price, and momentum—offering a highly liquid and low-cost way to capture the high-performing 'growth slice' of the broader U.S. large-cap market.
Read more on VOOG →
